Pub Date : 2019-01-29DOI: 10.20471/lo.2018.46.02-03.07
Anita Štefić, M. Skoko, Irena Mihić-Lasan, I. Kirac, K. Bilić, T. Vučemilo
Glasgow Prognostic Score (GPS) is such an infl ammation-based factor, defi ned by the combination of the level of serum C-reactive protein (CRP) and albumin, which are indicators of systematic infl ammatory response and nutritional status. A higher score is associated with a worse prognosis of diff erent tumor sites. The score is based on the immunomodulatory and infl ammatory status found in patients with elevated CRP. We hypothesized that there is a correlation between GPS and histopathological tumor characteristics and GPS and perioperative administration of erythrocyte concentrates in patients undergoing curative tumor resection. We retrospectively revied the data of fi fty-one consecutive patient who underwent elective colorectal surgery. We extracted the values of preoperative C-reactive protein(CRP) and albumin and calculated the GPS. We correlated the histopathology of cancer and perioperative transfusion with the outcome. GPS 0 and 2 having a tumor localized in the colon, with GPS 1 in the rectum. T4 tumor stage had patients only in the group of GPS 2 which was statistically signifi cant from the GPS 0 group. The GPS was not associated with the presence of metastases in the lymph nodes, lymphatic and perineural invasions, while a statistically signifi cant diff erence was present comparing GPS with tumor deposits between GPS 0 and GPS 1 and GPS 0 and GPS 2. Transfusions were statistically signifi cantly higher in GPS 2 group compared to GPS 0 and 1. A higher GPS score is associated with the changes of immune status of the tumor environment which can aff ect the recurrence of the disease and survival. GPS should be considered when recommending the frequency of follow up and therapy after curative tumor resection. We have shown that there is an increased risk for perioperative blood consumption, which may independently result in a worse prognosis of the underlying disease.
{"title":"Association of inflammatory status of patients with histopathological characteristics of colorectal tumors and perioperative transfusion requirements","authors":"Anita Štefić, M. Skoko, Irena Mihić-Lasan, I. Kirac, K. Bilić, T. Vučemilo","doi":"10.20471/lo.2018.46.02-03.07","DOIUrl":"https://doi.org/10.20471/lo.2018.46.02-03.07","url":null,"abstract":"Glasgow Prognostic Score (GPS) is such an infl ammation-based factor, defi ned by the combination of the level of serum C-reactive protein (CRP) and albumin, which are indicators of systematic infl ammatory response and nutritional status. A higher score is associated with a worse prognosis of diff erent tumor sites. The score is based on the immunomodulatory and infl ammatory status found in patients with elevated CRP. We hypothesized that there is a correlation between GPS and histopathological tumor characteristics and GPS and perioperative administration of erythrocyte concentrates in patients undergoing curative tumor resection. We retrospectively revied the data of fi fty-one consecutive patient who underwent elective colorectal surgery. We extracted the values of preoperative C-reactive protein(CRP) and albumin and calculated the GPS. We correlated the histopathology of cancer and perioperative transfusion with the outcome. GPS 0 and 2 having a tumor localized in the colon, with GPS 1 in the rectum. T4 tumor stage had patients only in the group of GPS 2 which was statistically signifi cant from the GPS 0 group. The GPS was not associated with the presence of metastases in the lymph nodes, lymphatic and perineural invasions, while a statistically signifi cant diff erence was present comparing GPS with tumor deposits between GPS 0 and GPS 1 and GPS 0 and GPS 2. Transfusions were statistically signifi cantly higher in GPS 2 group compared to GPS 0 and 1. A higher GPS score is associated with the changes of immune status of the tumor environment which can aff ect the recurrence of the disease and survival. GPS should be considered when recommending the frequency of follow up and therapy after curative tumor resection. We have shown that there is an increased risk for perioperative blood consumption, which may independently result in a worse prognosis of the underlying disease.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42179911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-29DOI: 10.20471/lo.2018.46.02-03.11
L. Vazdar, R. Šeparović, Ana Tečić-Vuger, M. Pavlovic, Nikolina Lonjak, C. Krstić
Systemic cytotoxic chemotherapeutic treatment of malignant tumors does not fully meet its goal due to the resistance of present tumor cells to the applied therapy. Chemoresistance is complex and multifactorial, caused by numerous mechanisms that alter drug concentration in the cell, by changes in expression of the epidermal growth factor and by activation of intracellular signaling pathways PI3K / Akt and MAPK. The factor of chemoresistance is also an increased level of antioxidative glutathione and glutathione transferase – S enzyme and the presence of tumor stem cells that signifi cantly improve protection of DNA from damage. Apart from cellular factors, resistance is infl uenced by extracellular hypoxia and acidosis and autophagy. Overcoming the chemoresistance is possible by using nanomechanisms for delivery of drugs to tumor cells, autophagy inhibitors like antimalarials chloroquine and hydroxychloroquine and plant polyphenols. By bett er understanding the mechanisms of chemoresistance and it’s overcoming it can be possible to achieve improvement in antitumor treatment.
{"title":"Association of tumor cells chemoresistance mechanisms and suboptimal systemic cytotoxic treatment results","authors":"L. Vazdar, R. Šeparović, Ana Tečić-Vuger, M. Pavlovic, Nikolina Lonjak, C. Krstić","doi":"10.20471/lo.2018.46.02-03.11","DOIUrl":"https://doi.org/10.20471/lo.2018.46.02-03.11","url":null,"abstract":"Systemic cytotoxic chemotherapeutic treatment of malignant tumors does not fully meet its goal due to the resistance of present tumor cells to the applied therapy. Chemoresistance is complex and multifactorial, caused by numerous mechanisms that alter drug concentration in the cell, by changes in expression of the epidermal growth factor and by activation of intracellular signaling pathways PI3K / Akt and MAPK. The factor of chemoresistance is also an increased level of antioxidative glutathione and glutathione transferase – S enzyme and the presence of tumor stem cells that signifi cantly improve protection of DNA from damage. Apart from cellular factors, resistance is infl uenced by extracellular hypoxia and acidosis and autophagy. Overcoming the chemoresistance is possible by using nanomechanisms for delivery of drugs to tumor cells, autophagy inhibitors like antimalarials chloroquine and hydroxychloroquine and plant polyphenols. By bett er understanding the mechanisms of chemoresistance and it’s overcoming it can be possible to achieve improvement in antitumor treatment.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46441844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-29DOI: 10.20471/lo.2018.46.02-03.19
Katarina Antunac
{"title":"Radiation-induced angiosarcoma of the breast - four case reports","authors":"Katarina Antunac","doi":"10.20471/lo.2018.46.02-03.19","DOIUrl":"https://doi.org/10.20471/lo.2018.46.02-03.19","url":null,"abstract":"","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41806646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-29DOI: 10.20471/LO.2018.46.02-03.12
Martina Mikulandra, L. Beketić-Orešković
Summary Partial breast irradiation is a relatively novel approach in adjuvant breast cancer radiotherapy. It involves administration of irradiation to a part of the breast, as opposed to the standard practice of irradiation of the whole breast. This method allows delivery of higher radiation dose to smaller volumes, and in shorter period of time. It can be delivered via standard linear accelerators, brachytherapy, or via mobile accelerator units which allow the delivery of a single dose of radiation to the tumor bed intraoperatively. However, the use of partial breast irradiation in standard clinical practice is still controver-sial. The level of evidence that supports its equality to the whole breast irradiation remains limited. While the results of some prospective randomized trials indicate its applicability in certain, highly selected patients, longer follow-up of patients is necessary to draw de fi nitive conclusions.
{"title":"Adjuvant radiotherapy of breast cancer - is partial breast irradiation sufficient?","authors":"Martina Mikulandra, L. Beketić-Orešković","doi":"10.20471/LO.2018.46.02-03.12","DOIUrl":"https://doi.org/10.20471/LO.2018.46.02-03.12","url":null,"abstract":"Summary Partial breast irradiation is a relatively novel approach in adjuvant breast cancer radiotherapy. It involves administration of irradiation to a part of the breast, as opposed to the standard practice of irradiation of the whole breast. This method allows delivery of higher radiation dose to smaller volumes, and in shorter period of time. It can be delivered via standard linear accelerators, brachytherapy, or via mobile accelerator units which allow the delivery of a single dose of radiation to the tumor bed intraoperatively. However, the use of partial breast irradiation in standard clinical practice is still controver-sial. The level of evidence that supports its equality to the whole breast irradiation remains limited. While the results of some prospective randomized trials indicate its applicability in certain, highly selected patients, longer follow-up of patients is necessary to draw de fi nitive conclusions.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47596981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-29DOI: 10.20471/LO.2018.46.02-03.13
P. Vuković, J. Raguž, L. Beketić-Orešković
Management of young women with breast cancer is complex and has several particularities, one of which is fertility preservation, a very important quality of life issue for young breast cancer survivors. Chemotherapy can be gonadotoxic and signifi cantly reduce woman`s reproductive potential and cause premature ovarian insuffi ciency while endocrine therapy requires a delay of pregnancy and indirectly aff ects fertility. Therefore every woman of reproductive age diagnosed with breast cancer should be informed about potential gonadotoxic eff ect of cancer treatment, the risk of premature ovarian insuffi ciency and associated symptoms, available fertility preservation methods, delay of cancer treatment and chances of subsequent pregnancy. If interested in fertility preservation breast cancer patients should be referred as early as possible to a reproductive specialist to further discuss the risk of infertility and available fertility preservation options. Currently established methods for fertility preservation are embryo and oocyte cryopreservation, while ovarian tissue cryopreservation, cryopreservation of immature oocytes and ovarian suppression with gonadotropin-releasing hormone agonists are still considered experimental. The aim of this review is to highlight the importance of fertility preservation as an important quality of life issue for young breast cancer survivors.
{"title":"Management of young women with early breast cancer – focus on fertility preservation","authors":"P. Vuković, J. Raguž, L. Beketić-Orešković","doi":"10.20471/LO.2018.46.02-03.13","DOIUrl":"https://doi.org/10.20471/LO.2018.46.02-03.13","url":null,"abstract":"Management of young women with breast cancer is complex and has several particularities, one of which is fertility preservation, a very important quality of life issue for young breast cancer survivors. Chemotherapy can be gonadotoxic and signifi cantly reduce woman`s reproductive potential and cause premature ovarian insuffi ciency while endocrine therapy requires a delay of pregnancy and indirectly aff ects fertility. Therefore every woman of reproductive age diagnosed with breast cancer should be informed about potential gonadotoxic eff ect of cancer treatment, the risk of premature ovarian insuffi ciency and associated symptoms, available fertility preservation methods, delay of cancer treatment and chances of subsequent pregnancy. If interested in fertility preservation breast cancer patients should be referred as early as possible to a reproductive specialist to further discuss the risk of infertility and available fertility preservation options. Currently established methods for fertility preservation are embryo and oocyte cryopreservation, while ovarian tissue cryopreservation, cryopreservation of immature oocytes and ovarian suppression with gonadotropin-releasing hormone agonists are still considered experimental. The aim of this review is to highlight the importance of fertility preservation as an important quality of life issue for young breast cancer survivors.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43563465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-29DOI: 10.20471/LO.2018.46.02-03.16
S. Kaštelan, Antonela Gverović-Antunica, L. Beketić-Orešković, Boris Kasun, K. Hat
{"title":"Uveal melanoma: an overview of management and prognosis","authors":"S. Kaštelan, Antonela Gverović-Antunica, L. Beketić-Orešković, Boris Kasun, K. Hat","doi":"10.20471/LO.2018.46.02-03.16","DOIUrl":"https://doi.org/10.20471/LO.2018.46.02-03.16","url":null,"abstract":"","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/LO.2018.46.02-03.16","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47781801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-29DOI: 10.20471/lo.2018.46.02-03.20
F. Cmrečak, Z. Rendić-Miočević, L. Beketić-Orešković
{"title":"Rare metastasis of breast cancer to mandible - a case report","authors":"F. Cmrečak, Z. Rendić-Miočević, L. Beketić-Orešković","doi":"10.20471/lo.2018.46.02-03.20","DOIUrl":"https://doi.org/10.20471/lo.2018.46.02-03.20","url":null,"abstract":"","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2018.46.02-03.20","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44014350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-29DOI: 10.20471/LO.2018.46.02-03.10
Lidija FumićDunkić, Antonia Kustura
The Republic of Croatia is in the process of establishing a palliative care system in all aspects of the health care system according to The National Program for Palliative Care Development 2017-2020. A curative and palliative treatment should be carried out simultaneously, from the time the diagnosis of life-limiting illnesses was made, as the illnesses progresses with reducing the share of curative treatment and increasing the proportion of palliative care. With the help of a well-organized palliative care system, the patient and family can have dignifi ed care and quality of life. Still, a large number of health professionals are not even aware of the existence and option of palliative care. Therefore, it is essential that the National Program for Palliative Care Development also continues the education of palliative care that should include all health workers. Implementation of palliative care into the health care system is a long-term process, but important steps have been taken so far, especially in urban areas, Zagreb and Rijeka.
{"title":"Organizational model of palliative care in the Republic of Croatia - where are we today?","authors":"Lidija FumićDunkić, Antonia Kustura","doi":"10.20471/LO.2018.46.02-03.10","DOIUrl":"https://doi.org/10.20471/LO.2018.46.02-03.10","url":null,"abstract":"The Republic of Croatia is in the process of establishing a palliative care system in all aspects of the health care system according to The National Program for Palliative Care Development 2017-2020. A curative and palliative treatment should be carried out simultaneously, from the time the diagnosis of life-limiting illnesses was made, as the illnesses progresses with reducing the share of curative treatment and increasing the proportion of palliative care. With the help of a well-organized palliative care system, the patient and family can have dignifi ed care and quality of life. Still, a large number of health professionals are not even aware of the existence and option of palliative care. Therefore, it is essential that the National Program for Palliative Care Development also continues the education of palliative care that should include all health workers. Implementation of palliative care into the health care system is a long-term process, but important steps have been taken so far, especially in urban areas, Zagreb and Rijeka.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/LO.2018.46.02-03.10","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49309583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-29DOI: 10.20471/LO.2018.46.02-03.08
Katarina Vučić, T. Orešić, Karolina Habljak, Marija Kahlina, I. Kirac, M. Šekerija
1Department for Safety and Effi cacy Assessment of Medicinal Products, Agency for Medicinal Products and Medical Devices, Zagreb, Croatia; 2Department of Surgical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 3Croatian National Cancer Registry, Department for Malignant Diseases, Croatian Institute of Public Health, Zagreb and Andrija Štampar School of Public Health, University of Zagreb School of Medicine, Zagreb, Croatia
{"title":"Regional differences of breast cancer risk factors in newly diagnosed female patients in Croatia","authors":"Katarina Vučić, T. Orešić, Karolina Habljak, Marija Kahlina, I. Kirac, M. Šekerija","doi":"10.20471/LO.2018.46.02-03.08","DOIUrl":"https://doi.org/10.20471/LO.2018.46.02-03.08","url":null,"abstract":"1Department for Safety and Effi cacy Assessment of Medicinal Products, Agency for Medicinal Products and Medical Devices, Zagreb, Croatia; 2Department of Surgical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 3Croatian National Cancer Registry, Department for Malignant Diseases, Croatian Institute of Public Health, Zagreb and Andrija Štampar School of Public Health, University of Zagreb School of Medicine, Zagreb, Croatia","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/LO.2018.46.02-03.08","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44026778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-29DOI: 10.20471/lo.2018.46.02-03.15
Katarina Antunac
Treatment options in subset of patients with high-risk prostate cancer are various: radical prostatectomy, hormonal therapy, radiation therapy, combined modality approach, addition of chemotherapy. Based on randomised trials data, optimal approach would consist of radical radiotherapy and long term hormonal therapy. If technically possible high dose radiotherapy, hypofractionation, image guided radiotherapy, simultaneous integrated boost on dominant intraprostatic lesion and HDR brachytherapy boost should be used as well.
{"title":"Optimal treatment of patients with high-risk prostate cancer","authors":"Katarina Antunac","doi":"10.20471/lo.2018.46.02-03.15","DOIUrl":"https://doi.org/10.20471/lo.2018.46.02-03.15","url":null,"abstract":"Treatment options in subset of patients with high-risk prostate cancer are various: radical prostatectomy, hormonal therapy, radiation therapy, combined modality approach, addition of chemotherapy. Based on randomised trials data, optimal approach would consist of radical radiotherapy and long term hormonal therapy. If technically possible high dose radiotherapy, hypofractionation, image guided radiotherapy, simultaneous integrated boost on dominant intraprostatic lesion and HDR brachytherapy boost should be used as well.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44751708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：